Результаты поиска

Лечебно-стойкий провокационный демиелинирующий псевдоопухоль с марбургскими особенностями: подход, основанный на описательном обзоре лечения.

Воспламенительное демиелинирование псевдотумора (ИДП) имитирует внутричерепные новообразования как с точки зрения клинического представления, так и с точки зрения изображений. МВУ с марбургскими особенностями представляют собой серьезную форму подстрекательского демиелинационного энцефаломиэлита, отмеченного драматическим наступлением, агрессивным курсом, отсутствием ремиссии и наличием повреждений центральной нервной системы, подобных опухоли. Ключевые характеристики ВПЛ в магнитно-резонансной съемке мозга включают в себя открытое или неполное расширение кольца, низкое значение обода Т2, огра

Совпадение в полном тексте источника
… METHODS A literature search was conducted using PubMed, Web of Science, and Google search engines for original articles published up to September 2024. …

Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report.

Anaphylactic reactions at the time of chimeric antigen receptor T (CAR-T) cell infusion are adverse events that have not been reported in pivotal clinical trials or in real-world series. We report the case of patient with severe anaphylaxis with cardiac arrest after tisagenlecleucel injection for Diffuse Large B cell Lymphoma, who recovered after resuscitation and intensive care treatment; we also conducted a Food and Drug Administration Adverse Event Reporting System database analysis and found several cases of severe anaphlyaxis after CAR-T cell injection. Although not reported in pivotal CA

Рецепт 1 в диабете и его хронические осложнения: механизмы сигнализации и новые терапевтические достижения.

Диабет моллюсков (DM) — системное метаболическое расстройство, характеризующееся хронической гипергликемией, которая может оказывать воздействие на почки, сетчатку, периферийные нервы и сердечно-сосудистую систему, что в конечном счете приводит к многочисленным хроническим осложнениям. 1 (PAR1) — G-белковый рецептор, приводимый в действие через каноническое декольте, например тромбинированный декольте и неканоническое декольте, например, декольте с помощью активированного белка C или матрицы Metalloproteinase-1. Эти режимы активации инициируют различные каналы подачи сигналов вниз по течению,

The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.

Glioblastoma (GBM) is an aggressive and common form of central nervous system primary malignant tumor in adults. GBM accounts for about half of all gliomas. Despite maximal resection, radiotherapy, and temozolomide, median survival is still 12-15 months because of tumor heterogeneity, diffuse infiltration, and therapeutic resistance. Recurrence is nearly universal, underscoring the need for novel therapies. Oncolytic virotherapy demonstrates a promising strategy that combines direct tumor cell lysis with immune activation. Tumor-selective viruses replicate within malignant cells, induce cell d

Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours.

(1) Background/Objectives: Primary and secondary brain tumours often hold devastating prognoses and low survival rates despite the application of maximal neurosurgical resection, and state-of-the-art radiotherapy and chemotherapy. One limiting factor in their management is that several antineoplastic agents are unable to cross the blood-brain barrier (BBB) to reach the tumour microenvironment. Nanomedicine could hold the potential to become an effective means of drug delivery to overcome previous hurdles towards effective neuro-oncological treatments. (2) Methods: A scoping review following th

The evolving global landscape of first-in-class oncology drug innovation.

First-in-class (FIC) oncology drugs-defined by their novel mechanisms of action or targeting of previously unaddressed molecular targets-have emerged as a leading force in cancer therapeutic innovation. In this Review, we delineate the global landscape of FIC oncology drug approvals between 2009 and 2024 and analyze the evolving characteristics of both approved FIC therapies and potential FIC (PFIC) candidates in clinical development. To clarify the underlying dynamics of this evolution, we construct an analytic framework encompassing four distinct archetypes of FIC development: new targets, n

Использование микробиомных средств для совершенствования методов лечения нейродегенеративных заболеваний: данные о воздействии вдоль оси микробиота-гут-мозгов.

Недавно в качестве полезной модели для понимания возникновения и развития нейродегенеративных заболеваний (НДД) появилась ось микробиота-гут-мозгов (МГБА). Меры воздействия на основе микробиома с использованием биотических добавок (пробиотики, предбиотики, синдиотики, постбиотики) могут модифицировать MGBA и служить подходящими решениями для снижения риска неврологических изменений, связанных с НИЗ, и регулирования симптомов. В настоящем описательном обзоре содержится резюме функционирования МГБС и его взаимодействия с заболеваниями, связанными с началом и развитием НИЗ. Проводится обзор мероп

An Experimental Investigation of Moral Self-Violation and Mental Contamination.

This paper describes the Data Domotopia a 2300 + respondent self-administered web-based survey. It includes 100 + multi-purpose items about home-making and stillness in a moving world. We suppose that home-making can reveal coping strategies and resilience practices to make everyday life work - as home is a central location in people's activity-travel patterns. To describe this phenomenon, the concept of Domotopia is introduced, defining how people arrange, use, and experience their homes to cope with the pathologies of accelerated and liquid modernity (Bauman 2005). While the Data Domotopia i

Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.

Lung cancer is a leading cause of morbidity and mortality in the United States and worldwide. The introduction of immune checkpoint inhibitors has led to a marked improvement in the outcomes of lung cancer patients. Despite these advances, there is a huge unmet need for therapeutic options in patients who are not candidates for targeted or immunotherapy or those who progress after first-line treatment. With its high mutational burden, lung cancer appears to be an attractive target for novel personalized treatment approaches. In this review, we provide an overview of two adoptive cell therapy a

Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma.

Surgery with the assistance of conventional radiotherapy, chemotherapy and immunotherapy is the basis for head and neck squamous cell carcinoma (HNSCC) treatment. However, with these treatment modalities, the recurrence and metastasis of tumors remain at a high level. Increasingly, the evidence indicates an excellent anti-tumor effect of chimeric antigen receptor T (CAR-T) cells in hematological malignancy treatment, and this novel immunotherapy has attracted researchers' attention in HNSCC treatment. Although several clinical trials have been conducted, the weak anti-tumor effect and the side

SiMON-PRO-Hematology®: Digital techology for pharmacotherapeutic and patient reported outcomes monitoring in patients with hematologic malignancies.

INTRODUCTION: Advances in hematologic malignancy treatment have improved survival, but patients often experience treatment-related toxicities. Traditional clinical follow-up often overlooks the patient's subjective experience, highlighting the need for integrated patient-reported outcome measures (PROMs). The primary objective of this study was to describe the design and implementation of the SiMON-PRO-Hematology® system, a comprehensive information tool supporting the pharmacotherapeutic follow-up of patients with hematological malignancies. A secondary objective was to detail the process for

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?

Chimeric antigen receptor T-cell (CAR-T) therapy is a new advancement in hematology and oncology with its use in treating many refractory malignancies. Cytokine release syndrome (CRS) is CAR-T's clinically hazardous side effect, ranging from mild to life-threatening events. It was one of the first side effects detected with CAR-T. We conducted a literature review using PubMed (MeSH) to study CRS incidence after the administration of CAR-T to reflect its clinical importance. Nine studies are mentioned, with a total of 1357 patients enrolled for different types of refractory/relapsed cancers, an

Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.

BACKGROUND: Cancer represents a major global public health issue, and recent research has focused on improving the efficacy of existing therapeutic approaches. In this context, oncolytic viruses have emerged as promising treatment options for advanced and treatment-resistant malignancies. Among them, adenoviruses are the most extensively studied due to their favourable safety profile, biological versatility and ease of genetic modification to enhance therapeutic performance. MAIN BODY: Combination-based strategies integrating virotherapy with chemotherapy, radiotherapy or immunotherapy have b

Иммунотерапия рака: текущие достижения и будущие направления.

Иммунотерапия обеспечивает фундаментальный сдвиг в лечении множественных раковых заболеваний, что дает надежду пациентам с раком. В отличие от обычных методов лечения, он использует иммунную систему пациента для точного выявления и уничтожения раковых клеток. Замечательный путь иммунотерапии революционизировал онкологию и проложил путь к развитию современной иммунотерапии. Для иммунотерапии применяется ряд подходов, включая ингибиторы иммунной системы, приемные клеточные препараты, вакцины от рака, перепрограммирование опухолей, моноклональные антитела, цитокиновую терапию, онколитную терапию

Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice.

The advent of cancer immunotherapies, including immune checkpoint inhibitors (ICI), Chimeric antigen receptor (CAR-T) cell therapies, and bispecific antibodies and other immune-activating platforms such as therapeutic vaccines and oncolytic viruses (often used in combination regimens) has revolutionized oncology by improving patient outcomes across diverse malignancies. However, these therapies are increasingly linked to cardiovascular toxicities such as myocarditis, arrhythmias, and heart failure, posing significant clinical challenges. Here we review current evidence on the mechanisms, clini

Serving Vietnam Veterans Hospitalized Outside the VA System: A Scoping Review of Presumptive Service-Related Illnesses and Presentations.

BackgroundRecent legislation, the MISSION Act and the PACT Act, expanded access to and utilization of non-Department of Veterans Affairs (VA) health care; more Veterans now receive care from non-VA healthcare providers. Hospitalists outside the VA may be less familiar with Veterans' service-related exposures and presumptive service-related conditions. We aimed to summarize research findings on service-related exposures and conditions among Vietnam War Veterans.MethodsUsing Arksey and O'Malley's methodological framework for scoping reviews, we searched PubMed, EMBASE, and Web of Science databas

CAR T-клеточная терапия для неврологических расстройств: научное обоснование и механистические исследования.

Разработка и успешное клиническое применение инженерных Т-клеток, содержащих синтетические химериковые антигенные рецепторы (CARs), является важной вехой в лечении рака. Этот подход оптимизирует физиологическую активацию в виво Т-клеток в отношении конкретных целевых антигенов, выраженных на определенных поднаборах клеток, с целью их глубокого и устойчивого истощения. Значительный прогресс был достигнут в реорганизации зданий ЦАР-Т-клеток в целях повышения безопасности, терапевтической эффективности и доступности. Усилия также были сосредоточены на рационализации обрабатывающей промышленности

Помимо CAR-T: Предотвращение и лечение релапса в гематологических злодеяниях B-Cell.

Цимерическая антигенная лейкемия (КАР) Т-клетотерапия произвела революцию в области лечения рентгеновской/рефракторной (R/R) острой лимфоболической лейкемии (B-LAL), неходгкинской лимфомы (NHL) и множественной миеломы (MM); однако значительная часть пациентов в конечном итоге, несмотря на первоначальные ответные меры, вновь заболела. В настоящем обзоре содержится краткий обзор клеточной терапии CAR-T, включая ее производственный процесс и связанные с этим токсичные свойства, до изучения биологических механизмов, лежащих в основе рецидива после CAR-T в B-ALL, NHL-особенно большой лимфомы B-клет

Methods of Topical Administration of Drugs and Biological Active Substances for Dental Implants-A Narrative Review.

Dental implants are, nowadays, established surgical devices for the restoration of lost teeth. Considered as an alternative for traditional prosthetic appliances, dental implants surpass them in reliability and patient feedback. Local drug delivery around the implants promotes osseointegration and reduces peri-implantitis. However, there are currently no methods of a multiple, precise topical administration of drugs to the implant area. Engineering coatings on the implants, drug application on carriers during implantation, or gingival pockets do not meet all requirements of dental surgeons. Th

Design thinking in cancer care: A systematic literature review.

ObjectiveCancer can have a profound impact on the life of the patient, presenting challenges such as dealing with complex healthcare models and psychological burden. Implementing design thinking (DT) in cancer care can improve the quality of life for patients. Although DT has been used in healthcare, there is limited research highlighting use of DT in cancer care. The objective of this review is to explore the applications of DT within a cancer care context.MethodsWe systematically searched databases (PubMed Central, Scopus, and Medline) for relevant papers published between January 2018 and M